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ABSTRACT
Mutations affecting Gαq proteins are pervasive in uveal melanoma (UM), 
suggesting they ‘drive’ UM pathogenesis. The ERK1/2-MAPK pathway is critical for 
cutaneous melanoma development and consequently an important therapeutic target. 
Defining the contribution of ERK1/2-MAPK signalling to UM development has been 
hampered by the lack of an informative animal model that spontaneously develops UM. 
Towards this end, we engineered transgenic zebrafish to express oncogenic GNAQQ209P 
in the melanocyte lineage. This resulted in hyperplasia of uveal melanocytes, but 
with no evidence of malignant progression, nor perturbation of skin melanocytes. 
Combining expression of oncogenic GNAQQ209P with p53 inactivation resulted in earlier 
onset and even more extensive hyperplasia of uveal melanocytes that progressed to 
UM. Immunohistochemistry revealed only weak immunoreactivity to phosphorylated 
(p)ERK1/2 in established uveal tumours—in contrast to strong immunoreactivity in 
oncogenic RAS-driven skin lesions—but ubiquitous positive staining for nuclear Yes-
associated protein (YAP). Moreover, no changes were observed in pERK1/2 levels 
upon transient knockdown of GNAQ or phospholipase C-beta (PLC-β) inhibition in the 
majority of human UM cell lines we tested harbouring GNAQ mutations. In summary, 
our findings demonstrate a weak correlation between oncogenic GNAQQ209P mutation 
and sustained ERK1/2-MAPK activation, implying that ERK1/2 signalling is unlikely 
to be instrumental in the maintenance of GNAQQ209P-driven UMs.
INTRODUCTION
Uveal melanoma (UM), the most prevalent primary 
malignancy of the human eye, originates principally 
from melanocytes residing within the choroid. While 
effective treatments are available for primary tumours, 
approximately half of patients will develop metastases 
within 15 years following diagnosis, for which currently 
there is no effective treatment [1, 2]. This has created a 
pressing need to understand the molecular pathogenesis of 
the disease. Earlier studies had focused on the contribution 
of ERK1/2-MAPK pathway to UM development, since 
this pathway was implicated in cutaneous melanoma (CM) 
[3] that has some obvious parallels to UM. However, 
mutations in well-known CM oncogenes such as BRAF or 
NRAS that are responsible for constitutive ERK activation 
are conspicuously rare in UM [4, 5]. Major advances in 
our understanding of the molecular events that drive 
UM initiation and progression have subsequently arisen 
through re-sequencing UM genomes, resulting in the 
identification of several candidate oncogenes and tumour 
suppressor genes. Recurrent hypermorphic mutations 
of GNAQ or GNA11 (GNAQ/11), highly related Gαq 
proteins, mainly affecting Glutamine 209 have been 
detected in UM and are proposed as indirect activators 
of ERK signalling via phospholipase C-beta (PLC-β)-
mediated activation of protein kinase C (PKC) [6–8]. 
However, GNAQ mutation and ERK activation are not 
correlated in clinical specimens [9], and clinical trials 
have so far shown little or no activity for PKC or MEK 
antagonists in patients with metastatic UM, prompting 
the question as to whether there may be other more 
               Research Paper
Oncotarget39655www.impactjournals.com/oncotarget
relevant targets. Recent studies indicate that activation 
of the transcription factor Yes-associated protein (YAP), 
independently of PLC-β, appears to sustain proliferation 
and survival in UM cells [10, 11].
GNAQ/11 mutations do not correlate with 
clinical, pathological, and genetic indicators of tumour 
progression [7, 12], suggesting that they are early events 
in UM development and insufficient for malignant 
progression. Consistent with this notion, forced expression 
of GNAQQ209L was insufficient to transform primary 
melanocytes [6]. In keeping with all other solid cancers, 
multiple genetic and epigenetic changes likely underlie 
progression of uveal melanocytic neoplasia from benign 
hyperproliferation to infiltrative and metastatic spread. 
In UM, loss-of-function BRCA1 associated protein-1 
(BAP1) mutations correlate with metastatic behaviour 
[13]. A significant body of evidence also indicates that the 
p53 pathway is abrogated in UM, and that the principal 
mechanism is likely the up-regulation of MDM2. Strong 
immunostaining of nuclear MDM2 was detected in 31/32 
(97%) of primary UM, but not normal uveal melanocytes 
[14]. In further support, transcriptome profiling of a 
human UM cell line, followed by validation on a larger set 
of UM cell lines, implied the abrogation of a p53-driven 
gene expression program in UM cells, as compared to 
normal choroidal melanocytes [15]. Finally, functional 
inactivation of signalling downstream of p53 was detected 
in UM cells following irradiation, possibly explaining the 
radioresistance of UM [16].
UM is a rare cancer, and hence clinical trials to 
determine the efficacy of novel drugs are difficult to 
organize, requiring multicentre collaboration. Animal 
models are thus an invaluable patient surrogate, which 
can be used not only to investigate factors involved in 
pathogenesis, but also to examine responses to therapy. 
A number of transplantation models are available that 
model UM including patient-derived xenografts (PDX) 
[17]; however, transplantation models suffer from 
altered tumour cell behaviour due to in vitro adaptation, 
as well as a requirement for immune suppression in 
the host. The limitations of transplantation models can 
be addressed in genetically engineered animal models 
spontaneously developing UM. Previously, we and others 
have succeeded in engineering zebrafish model of CM 
through targeting expression of oncogenic RAS and 
BRAF to the melanocyte lineage [18, 19]. These models 
have generated considerable insights into the pathogenesis 
of CM [20–22], and also yielded a novel clinical drug 
candidate [23]. Herein, we describe the generation of 
transgenic zebrafish expressing oncogenic GNAQQ209P in 
the melanocyte lineage, yielding a model of benign uveal 
melanocytic hyperplasia which confirms the selective 
role of Gαq proteins in driving the proliferation of uveal 
melanocytes. To test whether oncogenic Gαq signalling 
co-operates with abrogation of p53 function in promoting 
disease progression, GNAQQ209P was misexpressed in a 
p53 loss-of-function genetic background. This resulted 
in the generation of an experimental model of UM 
progression that likely reflects the contribution of MDM2 
overexpression in human UM. Moreover, we present data 
that calls into question the contribution of oncogenic 
GNAQ to ERK activation in UM.
RESULTS
Construction of a Tol2-based transposon 
oncogenic GNAQQ209P transgene
As a first step toward creating a genetically 
engineered zebrafish model of UM, human and zebrafish 
GNAQ protein sequences were aligned using BLAST 
software. This revealed a highly conserved GNAQ 
orthologue in zebrafish (Supplementary Figure S1). 
In order to drive oncogenic GNAQQ209P expression in 
zebrafish choroidal melanocytes from a transgene, it 
was first necessary to identify an appropriate promoter. 
We previously used a fragment from the mitfa promoter 
to direct oncogene expression to zebrafish cutaneous 
melanocytes, which resulted in CM development [18]. 
In embryos, endogenous mitfa is expressed not only in 
cutaneous melanocytes, but also in uveal melanocytes and 
the retinal pigmented epithelium (RPE) [24, 25]. However, 
the mitfa promoter fragment, employed by us and others, 
drives detectable reporter expression only in melanocytes 
[26]. Moreover, we observed that mitfa nullizygous 
(nacre) zebrafish lack choroidal melanocytes, but as 
previously reported [24], the RPE appears structurally 
normal (Supplementary Figure S2).
To generate oncogenic GNAQ cDNA, wild-type 
zebrafish GNAQ coding sequence was mutagenized to 
substitute the conserved Glutamine (Q) at position 209 with 
Proline (P). Glutamine 209 of GNAQ is similar to Glutamine 
61 of RAS proteins: substitution results in a conformational 
change, leading to the loss of intrinsic GTPase activity 
and sustained signalling. We then constructed a Tol2-
based transposon vector incorporating the mitfa promoter 
fragment and oncogenic GNAQQ209P cDNA (Figure 1A). The 
transposon construct also comprised a second expression 
cassette that allowed the rapid identification of transgene 
carriers through driving Venus GFP expression in the eye 
lens (Figure 1B). Following sequence verification, the 
GNAQQ209P construct was co-injected with Tol2 transposase 
mRNA into one-cell stage wild-type zebrafish embryos. 
Potential founders were identified while embryos by 
screening for GFP expression in the lens, and then grown 
and mated to wild-type zebrafish to generate a first filial 
F1 generation (again identified by GFP positive lenses). To 
validate the expression of the oncogene, RNA was extracted 
from dissected caudal fins of 2-month-old F1 adult transgenic 
zebrafish then converted to cDNA, which was used as a 
template for real-time quantitative reverse transcription 
PCR (qRT-PCR) analysis. This revealed a 4.1 fold increase 
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Figure 1: Only oncogenic GNAQQ209P is sufficient to induce choroidal melanocyte hyperplasia. A. Schematic representation 
of elements in the Tol2-based transposon vector driving the expression of oncogenic GNAQQ209P under the control of zebrafish mitfa 
promoter in the melanocyte lineage and Venus fluorescent reporter under the control of cryaa promoter in the eye lens. Abbreviations: 
ITR, inverted terminal repeat. B. Example of a 5 dpf transgenic zebrafish embryo with a fluorescent eye lens. Scale bar, 100 μm. C. RT-
qPCR data showing a 4.1 fold increase in GNAQ expression in the melanocytes of 2-month-old F1 Tg (mitfa:GNAQ
Q209P) zebrafish, as 
compared to non-injected controls. Data represents mean ± SEM of triplicates of three independent experiments. *** P <0.05 using two-
tailed, unpaired t test. D, E, F, G. H&E staining of transverse sections of formalin-fixed and paraffin-embedded eye specimens of control 
wild-type, Tg (mitfa:GNAQQ209P), Tg (mitfa:NRASQ61L), and Tg (mitfa:BRAFV600E) zebrafish, respectively. Choroidal hyperplasia observed 
in the thickened choroid (E; black arrowhead) was only observed in transgenic animals expressing oncogenic GNAQQ209P. In contrast, as 
compared to control wild-type H. and Tg (mitfa:GNAQQ209P) I. hyperplasia of cutaneous melanocytes (black arrowhead) was only detected 
in transverse sections of the torso region of Tg (mitfa:NRASQ61L) J. and Tg (mitfa:BRAFV600E) K. zebrafish. Abbreviations: RPE, retinal 
pigmented epithelium. Scale bars, 20 μm.
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in GNAQ expression in transgenic zebrafish, as compared to 
non-injected controls (Figure 1C).
Mitfa-driven expression of oncogenic GNAQQ209P 
induces hyperproliferation of choroidal 
melanocytes
Cohorts of wild-type and transgenic F1 adult fish were 
sacrificed at two and five months of age for histological 
examination of the choroid. No changes were apparent at two 
months (data not shown), but multi-layering of the choroid 
was detected in approximately 65% (15/23) of five-month-
old Tg (mitfa:GNAQQ209P) zebrafish, with no structural or 
numerical aberrations detected in the RPE (Figure 1E); also 
no evidence of infiltration or perforation of the sclera was 
observed. We posited that the choroidal hyperplasia observed 
in F1 animals involving the entire uveal tract might be likened 
to ocular melanosis/melanocytosis in man (although this is 
not associated with GNAQ mutation [27]). The pathology 
was completely benign, as malignancy was not observed in 
these animals even after a year (data not shown).
While CMs frequently harbour activating 
mutations in either NRAS or BRAF genes, the vast 
majority of UMs arise independently of these two 
oncogenic mutations [28]. On the contrary, GNAQ 
mutations occur at a high frequency in UM, but are 
rarely detected in their cutaneous counterparts. Using 
transgenic zebrafish lines expressing oncogenic BRAF 
(BRAFV600E), NRAS (NRASQ61L), or GNAQ (GNAQQ209P) 
in the melanocyte lineage under the control of mitfa 
promoter, we attempted to directly contrast the ability 
of oncogenic GNAQQ209P on the one hand and NRASQ61L 
and BRAFV600E on the other to induce proliferative 
responses in uveal versus cutaneous melanocytes. Adult 
wild-type and transgenic zebrafish were euthanized 
and their histology was examined. In contrast to the 
choroidal hyperplasia observed in Tg (mitfa:GNAQQ209P) 
zebrafish, choroidal melanocytes were morphologically 
normal in all specimens of Tg (mitfa:NRASQ61L) 
(Figure 1F) and Tg (mitfa:BRAFV600E) (Figure 1G) 
zebrafish examined (for each, n>20). In contrast, 
hyperplasia of cutaneous melanocytes was evident in 
the hypodermis of Tg (mitfa:NRASQ61L) (Figure 1J) 
and Tg (mitfa:BRAFV600E) (Figure 1K) zebrafish, but not 
in Tg (mitfa:GNAQQ209P) zebrafish (Figure 1I). Thus, we 
conclude that zebrafish uveal melanocytes and cutaneous 
melanocytes appear to respond distinctly to different 
recurrently-mutated melanoma oncogenes, mirroring the 
pattern of genetic lesions detected in human UM and CM.
GNAQQ209P-driven hyperplastic lesions 
demonstrate restricted activation of ERK and 
YAP signalling
Activation of ERK1/2-MAPK signalling by 
oncogenic GNAQ mutations was first demonstrated 
in vitro by transient expression of mutant GNAQQ209L 
construct in hTERT/CDK4R24C/p53DD melanocytes, 
which resulted in increased expression of phosphorylated 
ERK (pERK), as compared to the same melanocytes 
transfected with GNAQWT or empty vector [6]. In 
addition, recent findings demonstrated the activation of 
transcription factor YAP in UM by GNAQ/11 oncogenes 
and highlighted its fundamental role in the maintenance 
of uveal tumours [10, 11]. Thus, to address the functional 
conservation of oncogenic GNAQ expression in our 
zebrafish model, hyperplastic lesions were examined 
for ERK and YAP activation by immunohistochemistry 
(IHC). For examining ERK status, hyperplastic lesions 
were stained with anti-pERK1/2 polyclonal antibody that 
detects activated ERK1 and ERK2 when phosphorylated 
at residues corresponding to Thr202/Tyr204 and Thr185/
Tyr187 in man respectively. IHC revealed positive 
immunoreactivity to pERK1/2 only within melanocytes 
at the interface between the RPE and choroid, where 
capillaries are concentrated (Figure 2C). Although less 
marked, YAP-positive nuclei were apparent at the same 
junctional zone (Figure 2D) — nuclear localization 
is critical for YAP-mediated oncogenic effects. Thus, 
the above findings indicate that zebrafish oncogenic 
GNAQQ209P can activate ERK1/2-MAPK and YAP 
signalling pathways, albeit restricted to melanocytes 
occupying a niche at the junction between the RPE and 
choroid. This indicates conserved functions of oncogenic 
GNAQ in zebrafish and man, and validates the transgenic 
line as a model of UM induction by oncogenic GNAQ.
GNAQQ209P expression restores pigmentation in 
melanocytes and RPE of golden zebrafish, and 
again with evidence of choroidal hyperplasia
Concerned that IHC on any resultant pigmented 
neoplastic lesions might be compromised by the presence 
of melanin and the necessity to bleach sections, we injected 
the GNAQQ209P transgene construct into zebrafish zygotes 
of golden mutants characterized by delayed and reduced 
melanin pigmentation in skin melanocytes and RPE, as a 
result of a loss-of-function mutation in the slc24a5 gene 
[29]. To our initial surprise, pigmentation was restored 
in transgenic embryos (that is those with fluorescent 
green lenses) starting at day 2 post-fertilization (Figure 
3C.I, 3C.II), and persisted in 49% of adult F0 transgenic 
zebrafish. Subsequent backcrossing from F0 founders to 
golden mutants resulted in an F1 generation with stable 
transgene incorporation, in which pigmentation was 
uniformly rescued (Figure 3F.I, 3G.I), and were visibly 
darker than non-injected golden (Figure 3E.I) and even 
wild-type (Figure 3D.I) zebrafish. Moreover, histological 
examination of transverse sections of eye tissues of 
2-month-old GNAQQ209P-expressing zebrafish revealed 
pigmentation-rescued RPE (Figure 3F.II, 3G.II), as 
compared to non-injected golden mutants (Figure 3E.II). 
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Transmission electron microscopy (TEM) confirmed 
the presence of abundant melanin-rich melanosomes 
in the melanocytes of dissected tail fins of GNAQQ209P–
expressing transgenics (Figure 3J.II, 3K.II), which as 
previously documented [29], were less densely pigmented 
in golden mutants (Figure I.II). qRT-PCR, which again 
confirmed increased expression of GNAQ in transgenic 
zebrafish, failed to reveal significant changes in the mRNA 
levels of key pigmentation genes such as mitfa, tyrosinase, 
tyrosinase-related protein-1 (tyrp1), or dopachrome 
tautomerase (dct), which might otherwise have accounted 
for the increased melanin synthesis (Figure 3L). Thus, 
we concluded that forced expression of GNAQQ209P in 
zebrafish melanocytes stimulates melanin production, 
although the mechanism is still unclear.
Notwithstanding the hyperpigmentation of 
GNAQQ209P-expressing zebrafish, which clearly 
demonstrated the activity of the transgene product 
throughout the melanocyte lineage, no other structural 
or numerical aberrations of choroidal or cutaneous 
melanocytes were yet apparent in F1 animals at two 
months of age. However, sectioning the eyes of 5-month-
old transgenics revealed thickening of the choroid by 
pigmented cells (Supplementary Figure S3C, S3D) in 70% 
of transgenic animals (n=10). No structural changes were 
observed in the RPE, apart from pigmentation rescue, 
which suggests though an activity of the construct in 
RPE cells too. To confirm that the observed thickening 
of the choroid was caused by the proliferation of uveal 
melanocytes, sections were bleached prior to hematoxylin 
and eosin (H&E) staining. This revealed multiple layers of 
cells in the choroid, distinguished by their nuclei, and with 
an overall morphology reminiscent of uveal naevocytes 
in man (Supplementary Figure S3F), indicating that the 
diffuse thickening of the choroid is a consequence of a 
proliferative event.
Figure 2: Oncogenic GNAQQ209P-mediated activation of ERK and YAP signalling in choroidal melanocytes at the 
junction between RPE and choroid. A-D. Transverse sections of formalin-fixed and paraffin-embedded eye tissues of F1 generation, 
5-month-old Tg (mitfa:GNAQQ209P) zebrafish. (A) H&E staining demonstrating choroidal hyperplasia (black arrowheads). White dashed box 
indicates the region of the choroid magnified in B-D. (B-D) Transverse sections of formalin-fixed and paraffin-embedded eye tissues were 
stained by IHC, visualized by ImmPact NovaRed peroxidase (HRP) substrate then counterstained with hematoxylin (blue). (B) Negative 
control: section incubated with 1x PBS instead of primary antibody. (C) Immunoreactivity to pERK1/2 (read-out of ERK activation; black 
arrowheads) in melanocytes at the interface between the RPE and choroid. (D) YAP-positive nuclei (read-out of YAP activation; black 
arrowheads) in the same cells. Scale bars, 20 μm.
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Figure 3: GNAQQ209P rescues the hypopigmentation phenotype of golden (slc24a5-/-) zebrafish. A.I, B.I, C.I. Lateral views 
of wild-type, golden, and Tg (mitfa:GNAQQ209P;slc24a5-/-) 5 dpf zebrafish embryos, respectively. A.II, B.II, C.II. Top views of wild-type, 
golden, and Tg (mitfa:GNAQQ209P;slc24a5-/-) 5 dpf zebrafish embryos, respectively. Scale bars, 100 μm. D.I, E.I, F.I, G.I. Lateral views 
of 2-month-old adult zebrafish. (D.I) Wild-type illustrating normal melanin pigmentation in skin melanocytes. (E.I) Light-skinned golden 
mutant (slc24a5-/-) with stripes comprising less melanin-rich melanocytes. (F.I, G.I) Two examples of Tg (mitfa:GNAQQ209P;slc24a5-/-) 
zebrafish from independent founders, acquiring darker stripes as compared to wild-type (D.I) and golden mutants (E.I), but still conserving 
the normal striped pigment pattern. Scale bars, 0.5 cm. D.II, E.II, F.II, G.II. H&E staining of transverse sections of formalin-fixed and 
paraffin-embedded eye specimens of 2-month-old adult zebrafish. (D.II) Normally pigmented RPE located between the photoreceptors 
layer of the retina (rods & cones) and the choroid in a wild-type zebrafish. (E.II) Lightly pigmented RPE in a golden mutant. (F.II, 
G.II) Rescuing of hypopigmented RPE in both GNAQQ209P-expressing golden mutants, with no pathological findings yet observed in the 
choroidal melanocyte layer. Scale bars, 50 μm. H.I, I.I, J.I, K.I. Tail fins of wild-type, golden, and two Tg (mitfa:GNAQQ209P;slc24a5-/-) 
zebrafish, respectively. These were dissected, fixed, and sectioned for TEM analysis. Black dashed boxes indicate representative regions 
of the tail fins examined by TEM. Scale bars, 0.5 cm. H.II, I.II, J.II, K.II. Transmission electron micrographs illustrating the structure of 
melanosomes in the melanocytes of dissected tail fins. Melanosomes in golden mutants (I.II) are less densely pigmented as compared to 
those of wild-type (H.II) and transgenic zebrafish (J.II, K.II). Scale bars, 200 nm. L. Relative to zebrafish EF1alpha (EF1α) expression and 
as compared to non-injected golden controls, qRT-PCR data show significant increase in mRNA expression levels of GNAQ in Tg (mitfa:G
NAQQ209P;slc24a5-/-) zebrafish. In contrast, no significant alterations were observed in the expression of mitfa or downstream differentiation 
genes including tyrosinase, tyrp-1, and dct. Results represent mean ± SEM of triplicates of three independent experiments. ***P <0.05, 
using two-tailed, unpaired t test. Abbreviations: tyrp-1, tyrosinase-related protein 1; dct, dopachrome tautomerase.
Oncotarget39660www.impactjournals.com/oncotarget
Co-operation of oncogenic GNAQQ209P with p53 
loss-of-function induces UM development
Interaction between an oncogenic driver and 
inactivation of p53 signalling has been mooted for 
malignant transformation of uveal melanocytes. To 
investigate this potential, we injected the oncogenic 
GNAQQ209P transgene construct into zygotes from 
homozygous p53M214K/M214K zebrafish mutants whose 
hypomorphic p53 closely resembles mutant forms 
isolated from human cancer [30]. As before, only 
animals with fluorescent lenses as embryos were 
retained. Again, those animals showed obvious choroidal 
hyperplasia; however, this was apparent earlier, that 
is at 2 months (Figure 4B.I). Bleaching of melanin of 
hyperproliferative choroid revealed multiple cellular 
Figure 4: Co-operation of oncogenic GNAQQ209P and p53 loss-of-function results in UM development. Oncogenic 
GNAQQ209P Tol2 construct was injected into p53-deficient (p53M214K/M214K) zygotes, animals were sacrificed at 2 and 5 months or sooner if 
ocular protrusion was prominent, then fixed eye specimens were processed and paraffin-embedded for transverse sectioning at a thickness 
of 5 μm, followed by H&E staining. Representative images are shown. A.I. A non-injected p53-deficient (p53M214K/M214K) control zebrafish 
illustrating a single layer of choroidal melanocytes. B.I. Benign choroidal hyperplasia in an 8-week-old Tg (mitfa:GNAQQ209P;p53M214K/M214K) 
zebrafish. Note the diffuse thickening of the entire choroid caused by the proliferation of choroidal melanocytes. Nuclear and plexiform 
layers of the retina, photoreceptors layer, and RPE are structurally normal. Also, sclera is respected, with no evidence of infiltration or 
perforation. C.I. An example of malignancy, with non-pigmented hyperproliferative atypical cells developing within an area that shows 
evidence of choroidal hyperplasia in a 20-week-old Tg (mitfa:GNAQQ209P;p53M214K/M214K) zebrafish. D.I. A second example of a 20-week-
old Tg (mitfa:GNAQQ209P;p53M214K/M214K) zebrafish developing an eye malignancy infiltrating the ciliary body, iris, and cornea, also with 
evidence of choroidal hyperproliferation. A.II, B.II, C.II, D.II. Magnifications of the regions within the white dashed boxes in A.I, B.I, 
C.I, D.I, respectively, illustrating the changes within the choroidal melanocyte layer (B.II, C.II, D.II), as compared to a structurally normal 
choroid in a non-injected control (A.II). (C.III, D.III) Magnifications of transformed uveal melanocytes depicted in the black dashed boxes 
in C.I and D.I, respectively. Abbreviations: RPE, retinal pigmented epithelium. Scale bar lengths, as indicated.
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layers (Figure 5A.II), and IHC staining confirmed 
GNAQ overexpression in hyperplastic cells (Figure 
5A.IV). However, sectioning a cohort of fifteen F0 Tg 
(mitfa:GNAQQ209P;p53M214K/M214K) zebrafish at 5 months 
of age revealed five (33%) with uveal tumours co-
existing with choroidal hyperplasia (Figure 4C.I, D.I), 
four (26%) displaying choroidal hyperplasia only 
without evidence of uveal malignancy, and two (13%) 
developing tumours in the leptomeninges surrounding 
the hindbrain (Supplementary Figure S4), while 
the remaining had normal phenotypes. Histological 
examination of the eye malignancies revealed non-
pigmented atypical cells developing in conjunction 
with heavily pigmented hyperproliferative choroidal 
melanocytes. Infiltration of the ciliary body, iris, and 
cornea was detected in one tumour specimen (Figure 
4D.I). In contrast, sectioning twelve non-injected p53 
mutant zebrafish at 5 months of age did not reveal any 
phenotypic changes in the uvea (Figure 4A.I). However, 
zebrafish p53 mutants may occasionally develop 
Figure 5: Validation of GNAQQ209P-driven choroidal hyperplasia and uveal tumours in Tg (mitfa:GNAQQ209P;p53M214K/
M214K) zebrafish. Transverse sections of formalin-fixed and paraffin-embedded zebrafish eye tissues were stained by IHC, visualized 
by ImmPact NovaRed peroxidase (HRP) substrate then counterstained with hematoxylin (blue). Representative H&E and IHC images 
are shown for the pre-malignant A.I-A.V. and malignant B.I-B.V. stages. (A.I) H&E staining illustrating a 5x magnification of a benign 
choroidal hyperplasia in a 2-month-old Tg (mitfa:GNAQQ209P;p53M214K/M214K) zebrafish. (A.II-A.V) Magnifications of the region depicted in 
the black dashed box in A.I. (A.II) H&E staining of a melanin-bleached section, revealing multiple cellular layers of the thickened choroid. 
(A.III) Negative control section for IHC staining. (A.IV) GNAQ expression in thickened choroid. (A.V) Hyperplastic choroidal melanocytes 
are positive for PCNA (dark brown nuclei), especially at the junctional zone between RPE and choroid. (B.I) H&E staining illustrating 
a 5x magnification of a uveal tumour developing in a 5-month-old Tg (mitfa:GNAQQ209P;p53M214K/M214K) zebrafish. (B.II) Negative control 
section for IHC staining. (B.III) Malignant cells expressing GNAQ. (B.IV) Positive immunoreactivity to the melanocytic differentiation 
marker tyrosinase, indicating the melanocytic origin of malignant cells. (B.V) Numerous PCNA-positive nuclei (dark brown) in malignant 
melanocytes. Abbreviations: Tyr, tyrosinase; PCNA, proliferating cell nuclear antigen. Scale bars, 100 μm (A.I, B.I); 20 μm (A.II-A.V; 
B.II-B.V).
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malignant peripheral nerve sheath tumours (MPNSTs) 
starting at 8.5 months of age [30], thus it was crucial to 
verify the origin of the observed eye tumours. To confirm 
that the malignancies observed following injection 
of GNAQQ209P transgene were linked to transgene 
expression, uveal tumour specimens were examined for 
GNAQ expression using IHC. In all samples, GNAQ 
was uniformly expressed by malignant cells (Figure 
5B.III). Tyrosinase, the rate-limiting enzyme controlling 
the synthesis of melanin pigment, has been validated 
as one of the key immunohistochemical markers for 
amelanotic melanomas [31]. IHC analysis revealed 
the expression of tyrosinase by malignant cells (Figure 
5B.IV), thus confirming the melanocytic origin of 
tumours. Furthermore, the transformed melanocytes 
were uniformly positive for the proliferation marker 
proliferating cell nuclear antigen PCNA (Figure 5B.V). 
This contrasted with PCNA being restricted to the 
interface between the choroid and RPE in pre-malignant 
lesions expressing GNAQQ209P (Figure 5A.V). Therefore, 
in parallel with cutaneous naevi, the junctional zone 
between the epithelium and supporting connective 
tissue appears to be a region of active proliferation in 
uveal naevi. Significantly, early CM develops at this 
junctional zone [32] and, in keeping, it is likely that this 
junctional zone also represents the site of origin of UM.
Figure 6: Sporadic ERK activation contrasted with ubiquitous nuclear YAP in malignancies in Tg 
(mitfa:GNAQQ209P;p53M214K/M214K) zebrafish. Sections of formalin-fixed and paraffin-embedded zebrafish eye specimens were stained 
for GNAQ, pERK1/2, and YAP by IHC, visualized by ImmPact NovaRed peroxidase (HRP) substrate then counterstained with hematoxylin 
(purple nuclei). A.I-A.III. Representative IHC images of benign hyperproliferative choroid. (A.I) Uniform expression of GNAQ in 
hyperplastic choroidal melanocytes. (A.II) Only a few cells (black arrowheads) are immunoreactive to pERK1/2. (A.III) Comparatively, 
more cells displayed nuclear YAP (brown nuclei), although again, this was more noticeable for cells residing at the interface. B.I-B.
III; C.I-C.III. Representative IHC images of malignant choroidal melanocytes in two independent GNAQQ209P-driven uveal tumours. 
(B.I, C.I) Transformed melanocytes expressing GNAQ. (B.II, C.II) Malignant cells showing only sporadic immunoreactivity to pERK1/2 
(cells showing positive immunoreactivity are indicated with black arrowheads). (B.III, C.III) Ubiquitous YAP nuclear localization (brown 
nuclei) in transformed uveal melanocytes. Images are representative of sections from three animals. Abbreviations: RPE, retinal pigmented 
epithelium; RBC, red blood cells. Scale bars, 20 μm.
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Nuclear YAP and not ERK phosphorylation 
correlates with malignant progression of uveal 
melanocytes
As revealed by IHC, pERK1/2-positive cells 
were sporadic in pre-malignant choroidal melanocytes 
expressing GNAQQ209P, again within the junctional zone 
(Figure 6A.II), and also in GNAQQ209P-expressing frank 
uveal tumours (Figure 6B.II, 6C.II). Nuclear YAP was also 
observed in pre-malignant uveal melanocytes, and again 
found to be enriched at the junctional zone (Figure 6A.III), 
but in contrast to pERK1/2, was ubiquitous in malignant 
uveal melanocytes (Figure 6B.III, 6C.III). Of note, strong 
immunoreactivity to pERK1/2 was readily detected in 
cutaneous tumours driven by the expression of oncogenic 
HRASG12V (Supplementary Figure S5C.V), indicating its 
capacity to maintain sustained ERK activation, which was 
barely evident in comparative GNAQQ209P-driven uveal 
tumours (Supplementary Figure S5D.V).
To further explore the link between Gαq 
hyperactivity and activation of ERK signalling, we 
transiently transfected human embryonic kidney (HEK) 
293 cells with empty vector, or vector encoding wild-
type GNAQ (GNAQWT), GNAQQ209P, or GNAQQ209L. 
Only the oncogenic forms (GNAQQ209P/L) resulted in 
ERK activation (Figure 7A), indicating that transient 
expression of oncogenic GNAQ can stimulate ERK. 
To determine whether oncogenic GNAQ signalling is 
required to maintain ERK activity, we next undertook 
knockdown of GNAQ in five established human UM cell 
lines: two expressing oncogenic GNAQQ209L (92.1 and 
Mel202), three expressing oncogenic GNAQQ209P (Mel270, 
OMM1.3, and OMM1.5), as well as two other cell lines 
expressing oncogenic BRAFV600E (OCM3 and OCM8). 
Following GNAQ knockdown, pERK1/2 levels remained 
unchanged in Mel202, Mel270, OMM1.3, and OMM1.5 
cells, and as expected in OCM3 and OCM8, but it was 
only the 92.1 cell line that responded differently, showing 
a marked decrease in pERK1/2 levels (Figure 7B). These 
effects were confirmed in a subset of UM cell lines by 
the enzyme-linked immunosorbent assay (ELISA) which 
demonstrated a significant decrease in pERK1/2 levels in 
GNAQ-silenced 92.1 cell line only, whereas no significant 
alterations were observed in pERK1/2 levels in GNAQ-
silenced Mel270 or OMM1.3 (Figure 7C). Moreover, 
treatment of UM cell lines with U-73122, a potent and 
selective PLC inhibitor, was not associated with any 
changes in pERK1/2 levels, excluding again 92.1 which 
showed reduced pERK1/2 levels (Figure 7D).
DISCUSSION
Using the Tol2-based transposon system, we 
genetically engineered zebrafish to express an oncogenic 
form of GNAQ (GNAQQ209P) under the control of the 
mitfa promoter to selectively target melanocytes. Despite 
the transgene being expressed throughout the melanocyte 
lineage, including in the skin, it was uveal (choroidal) 
melanocytes that demonstrated hyperproliferation 
(and presumably leptomeningeal melanocytes), and 
interestingly, it is precisely this subset of melanocytes 
in humans that predominantly develops into melanoma 
in response to GNAQ mutation. Conversely, expression 
of oncogenic NRASQ61L or BRAFV600E from the same 
promoter resulted in hyperproliferation of cutaneous but 
not uveal melanocytes. Again, in humans, it is epidermal 
melanocytes that develop into melanoma in response to 
NRAS or BRAF mutations. Thus, despite being unable 
to target transgenes specifically to uveal melanocytes, 
nevertheless, owing to the intrinsic selective responses of 
anatomical subsets of melanocytes to various oncogenic 
drivers recurrently mutated in melanoma, we were able 
to induce an early oncogenic event within the uveal 
melanocytes, with no interference from the RPE or 
cutaneous melanocytes.
Upon expression of GNAQQ209P in the melanocytes 
of zebrafish golden mutants, another effect we observed 
was its ability to rescue the reduced pigmentation caused 
by an inactivation of the slc24a5 gene required for 
melanosome formation and/or function [29]. This feature 
was observed in cutaneous melanocytes and RPE. In the 
mouse, hypermorphic GNAQ/11 alleles also resulted in 
darker skin and hair by two independent mechanisms: 
Gαq stimulation increased the proliferation of mouse 
embryonic dermal (but not epidermal) melanoblasts by 
bolstering signalling from the endothelin receptor B [33]. 
Gαq proteins also stimulated melanin synthesis by hair-
follicle associated melanocytes, resulting in darker hairs 
[34]. Hypermorphic Gαq proteins that affect mouse coat 
colour were still capable of GTP hydrolysis and were 
not reported to be oncogenic. In contrast, GNAQQ209L 
is compromised in GTP hydrolysis and is oncogenic 
[6, 10, 35]. Its forced expression in mouse melanocytes 
again resulted in expansion of dermal melanocytes, but 
to a reduction in melanin transfer to keratinocytes in the 
hair resulting in their greying [35]. In zebrafish, despite 
the requirement for endothelin receptor B signalling 
in pigment pattern formation [36], forced expression 
of GNAQQ209P did not appear to affect the proliferation 
of cutaneous melanocytes. The lack of a conserved 
proliferative response to stimulation of Gαq signalling 
between mouse and zebrafish cutaneous melanocytes 
may reflect a technical difference between the models 
(for example, timing, duration or amplitude of stimulation 
achieved), but might also reflect fundamental differences 
between cutaneous melanocytes in the two species: 
predominantly dermal in mouse, but also in hair follicles; 
while predominantly in the hypodermis in zebrafish, 
but also in the dorsal epidermis (in man, cutaneous 
melanocytes are predominantly in the epidermis). 
However, the involvement of Gαq in melanin synthesis 
appears conserved, although the mechanism is as yet 
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Figure 7: ERK1/2 activation in human UM cell lines harbouring GNAQ mutations is predominantly independent 
of GNAQ signalling. A. HEK 293 cells were transfected with vector alone (v) or plasmids encoding Myc-DDK tagged wild-type 
GNAQ or mutagenized GNAQQ209P/L. 48 hours later, expression of constructs was validated by immunoblotting whole cell lysates with 
anti-MycDDK antibody. Lysates were also probed for pERK1/2and total ERK1/2, revealing increased pERK1/2 levels upon expression of 
mutant, but not wild-type GNAQ or empty vector. GAPDH was used as a loading control. B. The indicated UM cell lines were transfected 
with control scrambled (Sc) siRNA or pre-designed and validated siRNA targeting human GNAQ. 48 hours post-transfection, cells were 
lysed and immunoblotting was performed for endogenous GNAQ, pERK1/2, and total ERK1/2. Knockdown of GNAQ in GNAQQ209P-
expressing UM cell lines (Mel270, OMM1.3, and OMM1.5), GNAQQ209L-expressing UM cell line (Mel202), as well as OCM3 and OCM8 
lines (expressing BRAFV600E; negative controls) was not associated with any alterations in pERK1/2 levels, as compared to cell lines 
transfected with Sc siRNA. For 92.1 only (expressing GNAQQ209L), pERK1/2 levels were reduced upon GNAQ knockdown. C. As detected 
by pERK1/2 sandwich ELISA, knockdown of GNAQ in 92.1 cell line was associated with a significant decrease in pERK1/2 levels, but 
didn’t affect pERK1/2 levels in Mel270 or OMM1.3. The corresponding immunoblot validates knockdown of GNAQ in the tested UM cell 
lines, as well as total ERK1/2 levels. Results represent the mean of absorbance readings at 450 nm ± SEM of three technical replicates. 
Data were analyzed for statistical significance using independent sample t-test at P <0.05. D. Treatment of the indicated UM cell lines 
withU-73122 (1μM), a PLC inhibitor, abolished ERK activation in 92.1 only, whereas the other cell lines showed steady levels of pERK1/2. 
Abbreviations: Sc, scrambled; Ctrl, control.
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unclear. Potentially Gαq proteins promote the formation 
or functioning of melanosomes.
Oncogenic GNAQQ209P alone was not sufficient to 
drive malignant transformation of uveal melanocytes. 
However, in co-operation with p53 loss-of-function, 
GNAQQ209P was able to promote uveal neoplasia. This is 
consistent with previous studies reporting the relatively 
weak oncogenic potential of mutant GNAQ/11 and their 
ability to transform only immortalized melanocytes 
that have been genetically altered to be deficient in the 
p53 and p16/CDK4/RB pathways [6]. Further, the vast 
majority of uveal melanocytic neoplasms with GNAQ/11 
mutations are benign, indicating that they require 
additional mutations to acquire metastatic potential. 
In the mouse, however, GNAQQ209L-expressing uveal 
melanocytes transformed readily and even developed 
distant metastases without the requirement to engineer 
further genetic modifications [35]. This could be explained 
on the basis that spontaneous abrogation of p53 function 
may be efficient in the mouse model, thus forgoing the 
requirement to engineer a ‘second hit’, or potentially 
tumour suppressor mechanisms mediated by p53 pose 
less significant obstacles to tumourigenesis in mouse uveal 
melanocytes than in zebrafish and man. A strength of our 
zebrafish model is therefore the parallels with human UM, 
as well as the ability to isolate initiation and progression 
steps in uveal melanocytic neoplasia, which we shall be 
exploiting in the near future to uncover molecular drivers 
of UM progression. Of note, a commonality between mice 
and zebrafish genetically engineered UM models is the 
occurrence of melanocyte-derived neoplasms developing 
within the leptomeninges, which is consistent with the 
previously reported presence of GNAQ/11 mutations in 
human melanocytomas of the CNS [35, 37, 38].
The UM and CM models we have created in 
zebrafish demonstrate a distinct dependency on driver 
mutation that mirrors the pattern of genetic lesions 
observed in human UM and CM. Oncogenic RAS and 
BRAF that potently stimulate ERK signalling drive 
neoplasia of cutaneous melanocytes in zebrafish and 
are commonly mutated in human CM, but mutations 
are vanishingly rare in UM. In contrast, oncogenic Gαq 
drives UM in zebrafish and man and also dermal ‘blue’ 
naevi in man, but mutations in these proteins are all but 
absent in CM. Why this pattern exists is not immediately 
obvious. Certainly, Gαq proteins are expressed in 
cutaneous melanocytes, and as we and others demonstrate, 
hyperactivation of Gαq proteins stimulates melanin 
synthesis in cutaneous melanocytes [34]. Moreover, 
overexpression of GNAQQ209L in human cutaneous 
melanocytes stimulated ERK and contributed to in vitro 
transformation [6], so might be expected to substitute for 
NRAS or BRAF in CM. What determines the differential 
sensitivity of uveal and cutaneous melanocytes to the 
various oncogenic driver mutations may ultimately 
be resolved by determining the developmental 
signalling networks operating in these anatomically and 
ontogenetically distinct melanocyte subsets.
Progression to UM in zebrafish was associated with 
enhanced YAP rather than ERK signalling. Only a small 
percentage of uveal melanocytes benign and malignant 
expressing GNAQQ209P showed evidence of ERK activation, 
as revealed by immunoreactivity to pERK1/2. One 
explanation for this observation is that the effect of GNAQ 
on ERK1/2-MAPK activation is restricted to a minority of 
cells, consistent with our findings from in vitro experiments, 
where knockdown of GNAQ or inhibition of PLC-β did not 
affect pERK1/2 levels in the majority of oncogenic GNAQ-
expressing UM cells. What limits the ability of oncogenic 
GNAQ to activate ERK signalling in the majority of 
transformed uveal melanocytes is currently unclear. An 
alternative explanation is that Gαq activates ERK only 
in short bursts. Certainly, Gαq-mediated activation of 
PLC-β is transient [39]. In contrast, other targets of Gαq 
proteins capable of functioning independently of PLC-β, 
as a consequence of Gαq-mediated activation of Trio and 
Rho GTPases, such as JUN and YAP, might be activated 
chronically and substitute for ERK signalling in driving cell 
proliferation [10, 11, 40].
To conclude, the genetically engineered zebrafish 
UM model we describe here joins the genetically 
engineered mouse models [35, 41, 42] as invaluable in 
vivo platforms for establishing the molecular drivers 
of UM. Particular strengths of our zebrafish system are 
the parallels with human UM development, technical 
simplicity, low cost with which genetic modification can 
be achieved, as well as the ability to segregate benign and 
malignant stages of neoplastic progression that should 
facilitate identification of genetic and epigenetic changes 
propelling this transition. Ultimately, we envisage our 
model also being used to validate therapeutic targets and 
establish the efficacy of experimental therapeutic agents.
MATERIALS AND METHODS
Zebrafish care and maintenance
Zebrafish were housed at the Biological Services 
Unit (BSU) at the University of Manchester and 
maintained at 28.5 °C under a 14-hour light/10-hour dark 
cycle. Embryos were collected and raised in chorion water 
(60 μg/ml instant ocean salt and 0.01% methylene blue) at 
28.5 °C up to 5 days post-fertilization (dpf), and thereafter 
on a recirculating system fed with live and powdered 
brine shrimps. Transgenic zebrafish expressing oncogenic 
BRAFV600E [Tg (mitfa:BRAFV600E)] or HRASG12V[Tg 
(mitfa:HRASG12V)] in the melanocyte lineage have 
been previously described [18]. Zebrafish husbandry 
and experimental studies conducted at the University 
of Manchester were performed in compliance with the 
Animals (Scientific Procedures) Act 1986 under a Home 
Office approved project licence.
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Generation of transgenic zebrafish expressing 
oncogenic GNAQQ209P and NRASQ61L
Recombinant plasmids expressing oncogenic GNAQQ209P 
and NRASQ61L
Zebrafish GNAQ cDNA cloned into the 
gateway-compatible pCMV-SPORT6.1 vector 
(IMAGp998G1219838Q) was purchased from Source 
Bioscience. To generate mutant GNAQQ209P, the 872 
bp insert was mutagenized using Quickchange II XL 
site-directed mutagenesis kit (Stratagene). Mutagenic 
oligonucleotides were designed using NEBase changer 
software (http://nebasechanger.neb.com), and were as 
follows: GNAQQ209P_Forward (Fwd): 5’-GATGTCGGG
GGTCCACGATCAGAAAG-3’ and GNAQQ209P_Reverse 
(Rev): 5’-CACCATCCTGAATATGACGCTTTG-3’. 
GNAQQ209P middle entry (ME) vector was created 
by recombining the mutagenized pCMV-SPORT6.1 
construct with pDONR221 in a reaction catalysed by 
BP clonase II plus enzyme mix (Life Technologies) 
according to the manufacturer’s instructions. NRASQ61L 
ME vector was created by amplifying NRASQ61L cDNA 
from a plasmid kindly supplied by Dr. Piero Crespo 
(IBBTEC Inicio, Universidad de Cantabria) using 
primers flanked with attB sites, and then recombining 
with pDONR221 by performing a BP reaction according 
to the manufacturer’s instructions. p5’E-mitfa promoter 
and p3’E-polyA entry clones were kindly provided by 
Dr. Craig Ceol (UMass Medical School), and Tol2-
pDest-cryaa:venus-polyA destination vector by Dr. 
Chi-bin Chien (University of Utah Medical Center). 
Invitro three-fragment recombination reaction between 
the entry clones (p5’E-mitfa promoter, pME-GNAQQ209P 
or pME-NRASQ61L, and p3’E-polyA) and Tol2-pDest-
cryaa:venus-polyA destination vector was catalysed 
using LR clonase II plus enzyme mix (Life Technologies) 
according to the manufacturer’s instructions to generate 
Tol2-pDest-cryaa:venus-polyA;mitfa:GNAQQ209P-polyA 
and Tol2-pDest-cryaa:venus-polyA;mitfa:NRASQ61L-
polyA recombinant expression plasmids. Clones were 
screened by colony PCR using att sites-specific primers 
for each of the three fragments, and their sequences were 
as follows:
p5’E_Fwd: 5’-CTATGACCATGATTACGCCAAG
CTA-3’,
p5’E_Rev: 5’-CTGCTTTTTTGTACAAACTTG-3’,
pME_Fwd: 
5’-CAAGTTTGACAAAAAAGCAG-3’,
pME_Rev: 
5’-CCACTTTGTACAAGAAAGCTG-3’,
p3’E_Fwd: 
5’-CAGCTTTCTTGTACAAAGTGG-3’, and
p3’E_Rev: 5’-CAGTGAATTATCAACTATGTA-3’.
Also, correct clones were further verified by 
sequencing and analyzed using DNA Dynamo sequencing 
analysis software.
Preparation of Tol2 transposase mRNA, microinjection, 
and screening of injected embryos
Tol2 transposase mRNA was synthesized from 
a NotI-linearized pCS2-TP plasmid, a kind gift from 
Dr. Koichi Kawakami (National Institute of Genetics), 
using the SP6 mMessage mMachine kit (Ambion) then 
purified using MEGAclear cleanup kit (Ambion). Injection 
mixture consisted of 5 μl of 0.4 M potassium chloride 
(KCl), 1 μl of phenol red solution (Sigma-Aldrich), 1 μl 
of 250 ng/μl Tol2 expression construct, 1 μl of 250 ng/
μl Tol2 transposase mRNA, and 2 μl of nuclease-free 
water (Ambion) to make up a total volume of 10 μl. An 
approximate volume of one nanoliter was injected into the 
cytoplasm of one-cell stage fertilized zebrafish embryos. 
Following injection, embryos were incubated in chorion 
water at 28.5 °C. At 5 dpf, transgenic carriers expressing 
the Venus green fluorescent protein (GFP) in the eye lens 
were identified using a Zeiss LumarV12 stereoscope, 
and images were captured with a Zeiss Axiocam MRc 
camera. Animals were then raised to adulthood and bred 
to generate F1 generations with stable incorporation of the 
transgene.
Fish preparation for histopathological 
examination
Adult zebrafish were sacrificed in accordance with 
the schedule 1 guidelines of of the Animal (Scientific 
Procedures) Act by excess anaesthesia then chemically 
preserved in 4% paraformaldehyde (PFA) in 1× phosphate 
buffered saline (PBS) for 2 days at 4 °C. Fish were then 
washed with 1× PBS (3 × 3 minutes) and decalcified in 
0.25 M EDTA (pH 8.0) for 2 days at room temperature. 
Following EDTA treatment, fish were washed with 
1× PBS (3 × 3 minutes) then processed using Shandon 
Excelsior TM carousel-type tissue processor (Thermo 
Fisher Scientific). Paraffin-infiltrated tissues were 
carefully embedded in hot paraffin wax using a Tissue-
Tek embedding station (Sakura) then allowed to set on a 
cold plate for 1 hour. Sections were cut at a thickness of 5 
μm using RM2035 Microtome (Leica) and subsequently 
stained with H&E dyes using Thermo Scientific Shandon 
automatic slide stainer (Thermo Fisher Scientific). 
Following staining, sections were mounted using Pertex 
mounting medium (Cell Path) and left to dry overnight at 
room temperature. Images were acquired with a [20x/0.80 
Plan Apo] objective using the 3DHistech Pannoramic 250 
Flash II slide scanner and processed using 3DHistech 
Pannoramic viewer software.
Immunohistochemical staining
Paraffin-embedded tissue sections (5 μm) were 
initially deparaffinized using xylene then rehydrated 
through a series of descending concentrations of ethanol. 
Antigen retrieval was performed by bringing the sections 
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to boil in 10 mM sodium citrate (pH 6.0), and then 
maintained at a sub-boiling temperature for 20 minutes 
and room temperature for 30 minutes. Where necessary, 
melanin was bleached by incubating sections with 3% 
H2O2 in 0.05 M phosphate buffer for 30 minutes at 55 
°C. Otherwise, endogenous peroxidase enzyme was 
inactivated using 3% H2O2in distilled water for 10 minutes 
at room temperature. Sections were then washed with 1x 
Tris-buffered saline and Tween 20 (TBST) and blocked 
with 5% normal goat serum/1x TBST for 1 hour at room 
temperature. Following blocking, sections were incubated 
with the primary antibody diluted in 5% normal goat 
serum/TBST according to the manufacturer’s instructions 
and left overnight at 4 °C. Primary antibodies used were: 
rabbit anti-GNAQ (Santa Cruz, 1:100 dilution), rabbit 
anti-PCNA (Abcam, 1:200 dilution), rabbit anti-tyrosinase 
(Santa Cruz, 1:100 dilution), rabbit anti-pERK1/2 (Cell 
Signalling Technology, 1:400 dilution), and rabbit anti-
YAP (Cell Signalling Technology, 1:200 dilution). The 
following day, sections were washed with 1x TBST then 
incubated with biotinylated goat anti-rabbit secondary 
antibody (Vector labs) diluted at 1/100 in 1x TBST for 1 
hour at room temperature. After washing, sections were 
incubated with avidin biotin complex (ABC) reagent 
(Vector labs) for 30 minutes at room temperature then 
developed with ImmPACT NovaRED Peroxidase (HRP) 
substrate (Vector labs) for 2 minutes at room temperature, 
gently washed with tap water, then counterstained with 
hematoxylin, dehydrated, and finally mounted with Pertex 
mounting medium (Cell Path) and left to dry overnight 
at room temperature. Sections were examined using Zeiss 
Axioplan2 upright microscope. Images were acquired with 
the AxioCam MRc color CCD camera and processed using 
AxioVision software.
Transmission electron microscopy (TEM)
TEM experiments were conducted at the electron 
microscope (EM) facility of the Faculty of Life Sciences 
at the University of Manchester. Tissue samples were 
clipped from the caudal fins of wild-type, golden, and 
transgenic GNAQQ209P adult zebrafish. Specimens 
were incubated in a tissue fixative (3% PFA, 3% 
glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4) for 
2 hours at room temperature then overnight at 4 °C, and 
finally post-fixed in 2% osmium tetroxide for 2 hours at 
0 °C. Specimens were block stained with 0.5% uranyl 
acetate in 50% ethanol for an overnight then dehydrated 
in a series of increasing concentrations of ethanol, 
followed by embedding in Epon 812 resin. Ultra-thin 
sections (70–80 nm) were prepared using a Reichert-Jung 
Ultramicrotome. TEM analysis was performed using a 
FEI Tecnai 12 Biotwin microscope, and photographs 
were taken using a CCD camera (Eagle, FEI Company). 
Images were acquired using an Imacon scanner and 
FlexColor software.
RNA extraction, cDNA synthesis, and 
quantitative PCR (qPCR) analysis
Total RNA was extracted from the caudal fin 
ends of adult zebrafish using TRIzol reagent (Life 
Technologies), followed by a column-based method 
of RNA purification using RNeasy mini kit (Qiagen). 
The purity and concentration of RNA were determined 
spectrophotometrically by measuring UV absorbances 
at wavelengths of 260 and 280 nm, using a Thermo 
Scientific Nanodrop™ 1000. First strand cDNA was 
then synthesized from 1 μg of total RNA using Tetro 
cDNA synthesis kit (Bioline). mRNA expression levels 
were determined using SYBR Green-based real-time 
quantitative PCR technique. All qPCR reactions were 
performed on Stratagene MX3000P real-time thermal 
cycler (Agilent Technologies) using SensiMix SYBR No 
Rox kit (Bioline). Primers used for qPCR analysis were 
designed using the PrimerQuest design tool (http://idtdna.
com/SciTools). qPCR primer sequences were as follows:
GNAQ_Fwd: 
5’-GAACACAATAAGGCCAATGCA-3’,
GNAQ_Rev: 
5’-CTGAGAGCTGGTATTCTCGTC-3’,
mitfa_Fwd: 
5’-TGTACAGCAATCATGCTCTTCC-3’,
mitfa_Rev: 
5’-GTCCCCAGCTCCTTAATTCTGTC-3’,
tyrosinase_Fwd: 
5’-CGCAGATGAACAATGGCTC-3’,
tyrosinase_Rev: 
5’-AGCAGATACACCCGATGCC-3’,
tryp1_Fwd: 5’-TGCTTGGCGACCCGTCGTTT-3’,
tyrp1_Rev: 5’-GGACGGGCCACGTTACCAGC-3’,
dct_Fwd: 
5’-ACCTGTGACCAATGAGGAGATT-3’, and
dct_Rev: 
5’-TACAACACCAACACGATCAACA-3’.
Zebrafish β-actin was used as a reference control 
to normalize gene expression, and had the following 
sequences: β-actin_Fwd: 5’-TGCGTCTGGATCTAGCT 
GG-3’ and β-Actin_Rev: 5’-TCCCATCTCCTGCTCGA 
AG-3’ Reactions were performed in triplicates and the 
analysis was independently replicated three times. Statistical 
analysis was performed using two-tailed, unpaired t test 
(GraphPad Prism software), with the significance level set 
to P <0.05.
Cell culture and procedures
HEK 293 cells (a kind gift from Prof. Claudia 
Wellbrock, University of Manchester) were cultured in 
L-glutamine/sodium bicarbonate-containing DMEM 
medium (Sigma-Aldrich). Established human UM cell 
lines 92.1, Mel270, OMM1.3, and OMM1.5 (kindly 
gifted by Prof. Sarah Coupland, University of Liverpool) 
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and OCM3 as well as OCM8 (kindly gifted by Dr. Pieter 
van der Velden, Leiden University Medical Centre) were 
cultured in L-glutamine/sodium bicarbonate containing-
RPMI 1640 medium (Sigma-Aldrich). Both media were 
supplemented with 10% fetal bovine serum (FBS; Life 
Technologies) and 1% penicillin & streptomycin (Sigma-
Aldrich). All cell lines were maintained at 37 °C in a 5% 
CO2 humidified incubator. Cells were grown to 80-90% 
confluency before passaging. Where indicated, cells were 
treated with 1 μM U-73122, a PLC inhibitor, for 10 hours.
Transient transfection
Human Myc-DDK tagged GNAQ cDNA cloned into 
mammalian pCMV6 vector was purchased from Origene. 
To generate mutant clones, wild-type GNAQ coding 
sequence was mutagenized using Quickchange II XL site-
directed mutagenesis kit (Stratagene). Mutagenic primers 
were designed using NEBase changer software (http://
nebasechanger.neb.com), and were as follows:
GNAQQ209P_Fwd: 5’-GATGTAGGGGGCCCAAGG
TCAGAGAG-3’
GNAQQ209L_Fwd: 5’-GATGTAGGGGGCCTAAGG
TCAGAGAG-3’, and
GNAQQ209P/L_Rev: 5’-CTTCTCTCTGACCTTTGG
CCCCCTACATCG-3’
One day before transfection, cells were seeded at 
a density of 2.5 x 105 per well of a 12 well plate format 
under complete growth conditions. Cells were transfected 
with plasmid DNA using FuGENE HD (Promega) or 
small interfering RNAs (siRNAs) using lipofectamine 
RNAiMAX (Life Technologies) as per the manufacturer’s 
guidelines.
Western blot analysis
For the preparation of whole protein extracts from 
cell cultures, cells were washed once with ice-cold 1x PBS 
then lysed in 1x radioimmunoprecipitation assay (RIPA) 
buffer (Sigma-Aldrich) freshly supplemented with protease 
and phosphatase inhibitors (GE healthcare). Samples were 
agitated for 30 minutes at 4 °C then centrifuged at 13,000 
rpm for 30 minutes. Following centrifugation, supernatant 
was collected, and protein content was quantified using 
bovine serum albumin (BSA) Bradford assay kit (Thermo 
Fisher Scientific) following the manufacturer’s instructions. 
Protein lysates were mixed with 4x Nupage lithium dodecyl 
sulfate (LDS) sample buffer (Life Technologies) at a 1:3 
(buffer:protein lysate) ratio then denatured by boiling for 5 
minutes at 95 °C. Whole cell extracts were fractionated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) at 200 volts for 1 hour using XCell SureLockTM 
Minicell Electrophoresis system (Life Technologies) then 
transferred onto nitrocellulose membranes (Biorad) using 
XCell IITM Blot module apparatus (Life Technologies). 
Membranes were blocked with 5% BSA/1x TBST for 1 
hour at room temperature then incubated with an appropriate 
dilution of the primary antibody for an overnight at 4 °C. 
Primary antibodies used were: rabbit anti-GNAQ (Santa 
Cruz, 1:1000 dilution), rabbit anti-ERK1/2 (Cell Signalling 
Technology, 1:2000 dilution), rabbit anti-pERK1/2 (Cell 
Signalling Technology, 1:2000 dilution), mouse anti-
MycDDK (Origene, 1:2000 dilution), and rabbit anti-
GAPDH (Cell Signalling Technology, 1:10,000 dilution). To 
remove excess unbound primary antibody, membranes were 
washed three times with 1x TBST buffer then incubated with 
an appropriate horseradish peroxidase (HRP)-conjugated 
secondary antibody (Cell Signalling Technology, 1:1000 
dilution) for 1 hour at room temperature. Finally, signals 
of specific proteins were detected by a chemiluminescent 
method using western blotting luminol reagent (Santa 
Cruz) according to the manufacturer’s instructions, and then 
captured using Optimax film processor. All immunoblotting 
procedures were performed in triplicate and generated 
comparable results.
Detection of endogenous levels of pERK1/2 using 
enzyme-linked immunosorbent assay (ELISA)
For preparing protein lysates, cells were washed 
once with ice-cold 1x PBS then lysed in 1x RIPA buffer 
(Sigma-Aldrich) freshly supplemented with protease 
and phosphatase inhibitors (GE healthcare). Samples 
were agitated for 30 minutes at 4 °C then centrifuged 
at 13,000 rpm for 30 minutes. The resulting supernatant 
(cell lysate) was then collected and analyzed for 
endogenous levels of ERK1/2 when phosphorylated at 
Thr202/Tyr204 using PathScan phospho-p44/42 MAPK 
(Thr202/Tyr204) sandwich ELISA kit (Cell Signalling 
Technology) following the manufacturer’s instructions. 
Results represent the mean of absorbances at 450 nm ± 
SEM of three technical replicates. Statistical analysis was 
performed using two-tailed, unpaired t test (GraphPad 
Prism software), with the significance level set to P <0.05.
ACKNOWLEDGMENTS
We would like to thank Dr. Helen Young from the 
Hurlstone laboratory for the construction of Tol2-pDest-
cryaa:venus-polyA;mitfa:NRASQ61L-polyA construct, as 
well as staff of the Biological Services Unit (BSU) for 
maintaining the zebrafish used in this study, and staff in 
the EM Facility for their assistance.
CONFLICTS OF INTEREST
The authors declare no competing interests.
FUNDING
This study was supported by a European Research 
Council grant (ERC-2011-StG-282059 PROMINENT) 
to A.H., a Faculty for the Future scholarship from the 
Oncotarget39669www.impactjournals.com/oncotarget
Schlumberger Foundation to M.A.M. Microinjection 
equipment used to generate transgenic zebrafish was 
purchased through a Wellcome Trust Institutional Strategic 
Support Fund (ISSF) award (097820/Z/11/A) to the 
University of Manchester.
Author contributions
M.A.M designed the study, performed all the 
experiments, analyzed the data, and assisted in the 
preparation of the manuscript. C.D. generated the NRASQ61L 
transgenic zebrafish line. As a consultant histopathologist, 
S.C. performed histological analyses of zebrafish uveal 
tumours and assisted in the revision of the manuscript. 
A.F.L.H devised the study and prepared the manuscript.
REFERENCES
1. Damato B, Heimann H. Personalized treatment of uveal 
melanoma. Eye. 2013;27:172-179.
2. Nathan P, Cohen V, Coupland S, Curtis K, Damato B, 
Evans J, Fenwick S, Kirkpatrick L, Li O, Marshall E, 
McGuirk K, Ottensmeier C, Pearce N, Salvi S, Stedman 
B, Szlosarek P, Turnbull N. Uveal Melanoma UK National 
Guidelines. Eur J Cancer. 2015;51:2404-2412.
3. Gray-Schopfer V, Wellbrock C, Marais R. 
Melanoma biology and new targeted therapy. Nature. 
2007;445:851-857.
4. Coupland SE, Lake SL, Zeschnigk M, Damato BE. Molecular 
pathology of uveal melanoma. Eye. 2013;27:230-242.
5. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, 
Packer L, Borgstein AM, Pavey S, van der Velden P, Out 
C, Jager MJ, Hayward NK, Gruis NA. Activation of the 
MAPK pathway is a common event in uveal melanomas 
although it rarely occurs through mutation of BRAF or 
RAS. Br J Cancer. 2005;92:2032-2038.
6. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, 
Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian 
BC. Frequent somatic mutations of GNAQ in uveal 
melanoma and blue naevi. Nature. 2009;457:599-602.
7. Onken MD, Worley LA, Long MD, Duan S, Council 
ML, Bowcock AM, Harbour JW. Oncogenic mutations in 
GNAQ occur early in uveal melanoma. Invest Ophthalmol 
Vis Sci. 2008;49:5230-5234.
8. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido 
MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, 
Green G, Bouvier N, Sozen MM, Baimukanova G, Roy 
R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher 
MR, O’Brien J, Bastian BC. Mutations in GNA11 in uveal 
melanoma. N Engl J Med. 2010;363:2191-2199.
9. Populo H, Vinagre J, Lopes JM, Soares P. Analysis of 
GNAQ mutations, proliferation and MAPK pathway 
activation in uveal melanomas. Br J Ophthalmol. 
2011;95:715-719.
10. Feng X, Degese MS, Iglesias-Bartolome R, Vaque 
JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander 
BR, Merlino G, Sodhi A, Chen Q, Gutkind JS. Hippo-
independent activation of YAP by the GNAQ uveal 
melanoma oncogene through a trio-regulated rho GTPase 
signaling circuitry. Cancer cell. 2014;25:831-845.
11. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, 
Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, 
Wang CY, Bastian BC, Zhang K, Guan KL. Mutant Gq/11 
promote uveal melanoma tumorigenesis by activating YAP. 
Cancer cell. 2014;25:822-830.
12. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de 
Klein A. Oncogenic GNAQ mutations are not correlated 
with disease-free survival in uveal melanoma. Br J Cancer. 
2009;101:813-815.
13. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, 
Worley LA, Council ML, Matatall KA, Helms C, Bowcock 
AM. Frequent mutation of BAP1 in metastasizing uveal 
melanomas. Science. 2010;330:1410-1413.
14. Brantley MA Jr, Harbour JW. Deregulation of the Rb 
and p53 pathways in uveal melanoma. Am J Pathol. 
2000;157:1795-1801.
15. An J, Wan H, Zhou X, Hu DN, Wang L, Hao L, Yan D, 
Shi F, Zhou Z, Wang J, Hu S, Yu J, Qu J. A comparative 
transcriptomic analysis of uveal melanoma and normal 
uveal melanocyte. PLoS One. 2011;6:e16516.
16. Sun Y, Tran BN, Worley LA, Delston RB, Harbour JW. 
Functional analysis of the p53 pathway in response to 
ionizing radiation in uveal melanoma. Invest Ophthalmol 
Vis Sci. 2005;46:1561-1564.
17. Laurent C, Gentien D, Piperno-Neumann S, Nemati F, 
Nicolas A, Tesson B, Desjardins L, Mariani P, Rapinat 
A, Sastre-Garau X, Couturier J, Hupe P, de Koning L, 
Dubois T, Roman-Roman S, Stern MH, Barillot E, Harbour 
JW, Saule S, Decaudin D. Patient-derived xenografts 
recapitulate molecular features of human uveal melanomas. 
Mol Oncol. 2013;7:625-636.
18. Michailidou C, Jones M, Walker P, Kamarashev J, Kelly 
A, Hurlstone AF. Dissecting the roles of Raf- and PI3K-
signalling pathways in melanoma formation and progression 
in a zebrafish model. Dis Model Mech. 2009;2:399-411.
19. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda 
JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, 
Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher 
DE, Zon LI. BRAF mutations are sufficient to promote 
nevi formation and cooperate with p53 in the genesis of 
melanoma. Curr Biol. 2005;15:249-254.
20. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando 
DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre 
F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, 
Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway 
LA, Young RA, Zon LI. The histone methyltransferase 
SETDB1 is recurrently amplified in melanoma and 
accelerates its onset. Nature. 2011;471:513-517.
Oncotarget39670www.impactjournals.com/oncotarget
21. Dalton LE, Kamarashev J, Barinaga-Rementeria Ramirez 
I, White G, Malliri A, Hurlstone A. Constitutive Rac 
Activation Is Not Sufficient to Initiate Melanocyte 
Neoplasia but Accelerates Malignant Progression. J Invest 
Dermatol. 2013;133:1572-81.
22. Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, 
Ablain J, Tan JL, Fogley RD, van Rooijen E, Hagedorn EJ, 
Ciarlo C, White RM, Matos DA, Puller AC, Santoriello C, 
Liao EC, Young RA, Zon LI. A zebrafish melanoma model 
reveals emergence of neural crest identity during melanoma 
initiation. Science. 2016; 351:aad2197.
23. White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl 
PB, Burke CJ, Langdon E, Tomlinson ML, Mosher 
J, Kaufman C, Chen F, Long HK, Kramer M, Datta 
S, Neuberg D, Granter S, Young RA, Morrison S, 
Wheeler GN, Zon LI. DHODH modulates transcriptional 
elongation in the neural crest and melanoma. Nature. 
2011;471:518-522.
24. Lane BM, Lister JA. Otx but not Mitf transcription factors 
are required for zebrafish retinal pigment epithelium 
development. PLoS One. 2012;7:e49357.
25. Lister JA, Close J, Raible DW. Duplicate mitf genes in 
zebrafish: complementary expression and conservation of 
melanogenic potential. Dev Biol. 2001;237:333-344.
26. Curran K, Raible DW, Lister JA. Foxd3 controls 
melanophore specification in the zebrafish neural crest by 
regulation of Mitf. Dev Biol. 2009;332:408-417.
27. Dratviman-Storobinsky O, Cohen Y, Frenkel S, Pe’er 
J, Goldenberg-Cohen N. Lack of oncogenic GNAQ 
mutations in melanocytic lesions of the conjunctiva as 
compared to uveal melanoma. Invest Ophthalmol Vis Sci. 
2010;51:6180-6182.
28. Cruz F, Rubin BP, Wilson D, Town A, Schroeder A, Haley 
A, Bainbridge T, Heinrich MC, Corless CL. Absence of 
BRAF and NRAS mutations in uveal melanoma. Cancer 
Res. 2003;63:5761-5766.
29. Lamason RL, Mohideen MA, Mest JR, Wong AC, Norton 
HL, Aros MC, Jurynec MJ, Mao X, Humphreville VR, 
Humbert JE, Sinha S, Moore JL, Jagadeeswaran P, Zhao 
W, Ning G, Makalowska I, McKeigue PM, O’donnell D, 
Kittles R, Parra EJ, Mangini NJ, Grunwald DJ, Shriver 
MD, Canfield VA, Cheng KC. SLC24A5, a putative cation 
exchanger, affects pigmentation in zebrafish and humans. 
Science. 2005;310:1782-1786.
30. Berghmans S, Murphey RD, Wienholds E, Neuberg D, 
Kutok JL, Fletcher CD, Morris JP, Liu TX, Schulte-Merker 
S, Kanki JP, Plasterk R, Zon LI, Look AT. tp53 mutant 
zebrafish develop malignant peripheral nerve sheath tumors. 
Proc Natl Acad Sci U S A. 2005;102:407-412.
31. Kaufmann O, Koch S, Burghardt J, Audring H, Dietel 
M. Tyrosinase, melan-A, and KBA62 as markers for 
the immunohistochemical identification of metastatic 
amelanotic melanomas on paraffin sections. Mod Pathol. 
1998;11:740-746.
32. Levene A. On the histological diagnosis and prognosis of 
malignant melanoma. J Clin Pathol. 1980;33:101-124.
33. Van Raamsdonk CD, Fitch KR, Fuchs H, de Angelis MH, 
Barsh GS. Effects of G-protein mutations on skin color. Nat 
Genet. 2004;36:961-968.
34. Van Raamsdonk CD, Barsh GS, Wakamatsu K, Ito S. 
Independent regulation of hair and skin color by two G 
protein-coupled pathways. Pigment Cell Melanoma Res. 
2009;22:819-826.
35. Huang JL, Urtatiz O, Van Raamsdonk CD. Oncogenic G 
Protein GNAQ Induces Uveal Melanoma and Intravasation 
in Mice. Cancer Res. 2015;75:3384-3397.
36. Parichy DM, Mellgren EM, Rawls JF, Lopes SS, Kelsh 
RN, Johnson SL. Mutational analysis of endothelin 
receptor b1 (rose) during neural crest and pigment pattern 
development in the zebrafish Danio rerio. Dev Biol. 
2000;227:294-306.
37. Koelsche C, Hovestadt V, Jones DT, Capper D, Sturm D, 
Sahm F, Schrimpf D, Adeberg S, Bohmer K, Hagenlocher 
C, Mechtersheimer G, Kohlhof P, Muhleisen H, Beschorner 
R, Hartmann C, Braczynski AK, Mittelbronn M, Buslei 
R, Becker A, Grote A, Urbach H, Staszewski O, Prinz 
M, Hewer E, Pfister SM, von Deimling A, Reuss DE. 
Melanotic tumors of the nervous system are characterized 
by distinct mutational, chromosomal and epigenomic 
profiles. Brain Pathol. 2015;25:202-208.
38. Kusters-Vandevelde HV, van Engen-van Grunsven IA, 
Coupland SE, Lake SL, Rijntjes J, Pfundt R, Kusters B, 
Wesseling P, Blokx WA, Groenen PJ. Mutations in g 
protein encoding genes and chromosomal alterations in 
primary leptomeningeal melanocytic neoplasms. Pathol 
Oncol Res. 2015;21:439-447.
39. Ross EM. Galpha(q) and phospholipase C-beta: turn on, 
turn off, and do it fast. Sci Signal. 2011;4:pe5.
40. Vaque JP, Dorsam RT, Feng X, Iglesias-Bartolome R, 
Forsthoefel DJ, Chen Q, Debant A, Seeger MA, Ksander 
BR, Teramoto H, Gutkind JS. A genome-wide RNAi screen 
reveals a Trio-regulated Rho GTPase circuitry transducing 
mitogenic signals initiated by G protein-coupled receptors. 
Mol Cell. 2013;49:94-108.
41. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, 
Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic 
mouse model for skin malignant melanoma. Oncogene. 
1998;17:1885-1888.
42. Schiffner S, Braunger BM, de Jel MM, Coupland SE, 
Tamm ER, Bosserhoff AK. Tg(Grm1) transgenic mice: a 
murine model that mimics spontaneous uveal melanoma in 
humans? Exp Eye Res. 2014;127:59-68.
